Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Minyan Mailbag: Biotech's Bottom

By non-advice forecast is that the BBH underperforms the IBB the rest of the year but both grind it out for the next 6-8 weeks within a range


Professor Miller,

Biotechs have been trying to bottom for several months now...maybe a break over 180 would be another indicator of where the Fed is headed (cash flows way in the future are more sensitive to rates)?

Biotechs aren't really my game, but the below chart did catch my attention...any thoughts?

Professor Adam Michael

Prof. Michael,

Finger in the air and hand-to-heart, my non-advice forecast is that the BBH underperforms the IBB the rest of the year but both grind it out for the next 6-8 weeks within a range. Take the temp again of the macro market (Is Ben really stopping?) at that point and I'll tell you how strong any year-end rally will be. That BBH chart looks for all the world like it's going to coil itself into a pennant and the IBB chart looks like what I used to call "airy" (not a good thing, but not shortable).

Fundamental wild cards (signposts a bullish bounce would come early in the seasonal cycle) are a redirection of the pharma money spigot to public companies, FASB placing its new acquisition accounting rules into effect in mid-2007 instead of December 2007 and a string of clinical and regulatory successes from the August/September trial data.

The risk side is even more trial and regulatory failures, but mostly macro issues like Bernanke, geopolitics, liquidity suckage, etc.

I'm still on the fence about what the mid-term elections mean for biotech, but I suspect Wall Street will make up its mind about that before too far into September. Of all the biotechs that come to mind, Genentech (DNA) has the biggest political risk as they are making many enemies due to the aggressive pricing of Lucentis and Avastin (one reason why I like IBB more than BBH).

Hope that helps...
Prof. Miller
< Previous
  • 1
Next >
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos